Desmopressin Acetate facilitates targeted therapeutic efficacy through high-affinity binding to V₂ receptors, bypassing systemic vasoconstrictive pathways:

• Antidiuretic Regulation: Selective agonism of renal tubular V₂ receptors triggers the apical translocation of aquaporin-2 (AQP2), maximizing free water reabsorption and increasing urine osmolality by 2,000–4,000 times compared to natural AVP.
• Hemostatic Support: Activation of endothelial V₂ receptors induces the rapid release of von Willebrand factor (vWF) from Weibel-Palade bodies, stabilizing Factor VIII (FVIII) and enhancing primary hemostasis without inducing V1-mediated hypertension.
• Metabolic Stability: The structural modification confers significant resistance against plasma vasopressinases, extending the clinical half-life to 1.5–3.5 hours, essential for formulating once-daily dosing regimens.

• Central Diabetes Insipidus (CDI): Essential API for replacement therapy to manage polyuria and polydipsia.
•  
• Hematological Hemostasis: Indicated for the management of mild Hemophilia A and von Willebrand's disease (Type I).
•  
• Pediatric Enuresis: Optimized for oral melt and nasal delivery systems targeting nocturnal polyuria.

Yes. We provide comprehensive regulatory support for global drug filings. This includes providing a full technical dossier (DMF-ready), Method of Analysis (MOA), and Letter of Access (LOA) to support your ANDA, MAA, or other regulatory submissions to the FDA, EMA, or NMPA.

How do you control the impurity profile and residual solvents (ICH Q3C) for this API?

Every batch of our Desmopressin Acetate is validated via HPLC/MS. We strictly control total impurities ≤ 1.5% and ensure that residual solvents comply with ICH Q3C guidelines. This ensures that the API is suitable for high-concentration parenteral and nasal formulations requiring maximum safety margins.

What measures are taken to prevent freezing during global cold chain transit?

Recognizing that peptide denaturation occurs upon freezing, we utilize validated **isothermal shipping containers** equipped with continuous temperature loggers. We coordinate with premium logistics partners to ensure the API remains strictly between 2-8°C from our facility to your manufacturing site.

Is the Desmopressin Acetate API certified as TSE/BSE-free and non-GMO?

Absolutely. Our Desmopressin is 100% synthetically derived via Solid-Phase Peptide Synthesis. We provide formal TSE/BSE-free statements and non-GMO certifications, confirming that no animal-origin materials are utilized in the synthesis or purification stages, simplifying your quality risk assessment.

Can you provide specific Particle Size Distribution (PSD) data for nasal or ODT formulations?

Yes. We support scalable procurement from 1g to multi-kilogram batches. For manufacturers developing oral disintegrating tablets (ODT) or intranasal systems, we provide customized PSD data and micronization services to ensure optimal dissolution and systemic absorption in your final dosage form.